APOE4 comes into view through vessels and cellular cleanup

# APOE4 comes into view through vessels and cellular cleanup OCTOBER 15, 2026 | LONGEVITY SPECIAL Two new studies from Mount Sinai suggest that APOE4, the strongest genetic risk factor for Alzheimer's disease, does active harm to the brain's blood vessels and its protein cleanup. In one study, blocking a signal called TGF-β reversed the blood vessel damage in the lab; the protein cleanup study showed impairment but no reversal. A genetic risk factor becomes more informative as its effects are traced through particular cells and pathways. These laboratory studies examine two such routes in the biology of Alzheimer's disease. The evidence is early. Both papers are laboratory work, not human trials. One, in the journal Cell, combined analysis of human brain tissue data with cell experiments and mouse brain tissue. The other, in Cell Stem Cell, used "miBrains," three-dimensional human brain-like tissue grown from stem cells in a dish. Neither tested a treatment in people. The abstracts available to us do not give sample sizes. The Cell study first asked why blood vessels in the brain deteriorate in Alzheimer's. The researchers built a single-cell atlas of human brain blood vessels, which maps gene activity cell by cell. In APOE4 carriers, they report, there were fewer pericytes, cells that wrap and support small vessels. A new population of cells that look like myofibroblasts, which produce scar-like tissue, appeared instead. Staining confirmed these cells in APOE4 human and mouse brains. According to the paper, APOE4 pericytes transform into these myofibroblasts. The new cells secrete a protein called fibronectin, which promotes amyloid buildup in vessel walls. The team identified raised signaling by a molecule called TGF-β as the driver. Blocking TGF-β restored pericyte coverage and reduced vessel scarring and amyloid to the levels seen with the common APOE3 version of the gene. The Cell Stem Cell study looked at a different problem: how the protein alpha-synuclein piles up. This protein is linked to Parkinson's disease and Lewy body dementia. As in the human brain, miBrains with two copies of APOE4 had more harmful alpha-synuclein. The researchers report that cholesterol accumulated in APOE4 astrocytes, support cells in the brain. That disrupted the cells' waste-disposal compartments, called endolysosomes, so soluble alpha-synuclein was not broken down properly. It then changed into a harmful form that seeded clumps in neurons. The abstract reports no reversal of this process. Why does cholesterol handling matter here? Because this work points to cholesterol inside brain support cells as a link between the APOE4 gene and failed cleanup. The studies do not examine cholesterol in the blood, diet, or cholesterol-lowering drugs. They offer no basis for changing any of those, and no one should start or stop any medication or supplement without talking to their clinician. For people who carry APOE4, the practical message is limited. APOE4 raises risk; it is not a diagnosis. These studies describe mechanisms that may explain part of that risk, and they suggest blood vessel damage may be a driver of disease rather than only a late result. Joel Blanchard, the corresponding author, said in Mount Sinai's release, as carried by ScienceDaily, that vessel damage "is a biologically active process caused by APOE4 that may be reversible." The coverage goes somewhat further than the abstracts. ScienceDaily says the TGF-β result was reproduced in aged APOE4 mice and describes the findings as pointing to treatment targets. The Cell abstract itself says only that the mechanism is "targetable." Blocking TGF-β affects many tissues, and the abstracts say nothing about safety. A dish or a mouse is a long way from a medicine that works safely in people. The argument is weakest here: reversal was shown only for the vessel findings, and only in the lab. WHAT TO WATCH NEXT Whether TGF-β blockers or cholesterol-focused approaches are tested for safety and benefit in APOE4 carriers, and whether other groups reproduce these results. The mechanisms offer places to ask better experimental questions. Turning either into treatment will require evidence that the intervention helps safely in people. Sources: Cell (2026), ScienceDaily (Icahn School of Medicine at Mount Sinai release; Cell and Cell Stem Cell) Cell (2026): https://doi.org/10.1016/j.cell.2026.08.058 ---